�Nutra Pharma Corp. (OTCBB: NPHC),
a biotechnology party that is developing drugs for HIV and Multiple
Sclerosis, has announced that its wholly-owned drug discovery
subsidiary, ReceptoPharm, has reported initial positive safety data
from its Phase IIb/IIIa clinical study of RPI-78M for treating
Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm's prima drug
nominee for treating neurological and autoimmune disorders.
"Initial reports and feedback from physicians involved with this
clinical study birth reported that patients birth experienced no adverse
side of meat effects from RPI-78M," explained Paul Reid, CEO of ReceptoPharm.
"This is an important index number of the success of this clinical study,
as it provides the medical and pharmacological communities with early
evidence supporting the safety of our leading drug candidate,
RPI-78M," he concluded.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder
that affects approximately 30,000 people global. The disorder is
characterized by the loss of the butterball covering (medulla sheath) on
nerve fibers within the brain (cerebral demyelination) and the
progressive degeneration of the adrenal gland (adrenal atrophy).
Neurological disability in AMN is slowly progressive over several
decades.
AMN interests the wider neurologic community because of its
similarities to Multiple Sclerosis (MS). There is currently no
approved treatment for AMN. Additionally, the disease's rarity
designates it as an orphan drug prospect both in Europe and in the
U.S. The Company has applied for Orphan drug status in the U.S. and
intends on doing so for the EU.
ReceptoPharm expects to deliver the complete clinical findings and
information from this study by the end of September.
About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical
products and technologies for the management of neurological
disorders, cancer, autoimmune and infectious diseases. Nutra Pharma
Corp. through its subsidiaries carries out basic drug discovery
research and clinical development and also seeks strategic licensing
partnerships to reduce the risks associated with the drug growing
process. The Company's subsidiary company, ReceptoPharm, Inc., is development
these technologies for the production of drugs for HIV and Multiple
Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is
engaged in the research and development of diagnostic test kits
intentional to be used for the speedy identification of infectious
diseases such as Tuberculosis (TB) and Mycobacterium
avium-intracellulare (MAI). Nutra Pharma continues to identify and
acquire rational property and companies in the biotech arena.
SEC Disclaimer This press release contains forward-looking statements. The speech or
phrases "would be," "will admit," "intends to," "will likely result,"
"are expected to," "will continue," "is awaited," "estimate,"
"project," or similar expressions ar intended to identify
"modern statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are
discussed in the Company's filings with the Securities and Exchange
Commission ("SEC").� The initial safety data from the clinical study
in Adrenomyeloneuropathy (AMN) should not be construed as an
meter reading in any way whatever of the value of the Company or its
common fund.� The Company's filings may be accessed at the SEC's
Edgar arrangement at world Wide Web.sec.gov.� Statements made herein are as of the
date of this press release and should not be relied upon as of whatsoever
subsequent date. The Company cautions readers not to place reliance on
such statements. Unless otherwise compulsory by applicable law, we do
not undertake, and we specifically disclaim any obligation, to update
whatever forward-looking statements to reflect occurrences, developments,
unanticipated events or luck after the date of such statement.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
More info
